ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Colgate Palmolive and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Colgate PalmoliveSanofi
studies on the registry1212,425
open to participants now14105
phase 3 studies under way761
reach primary completion within a year864
programswith a study of their own in two years3581+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseColgate PalmoliveSanofi
Phase 100%28%
Phase 2

Colgate Palmolive: 1 of its 35 programs at phase 2

  1. Vitamin C toothpastephase 2
3%

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%
Phase 371%

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%
Approved, new studies

Colgate Palmolive: 9 of its 35 programs at approved, new studies

  1. Tin Fluoridesapproved, new study
  2. Cetylpyridiniumapproved, new study
  3. zinc lactateapproved, new study
  4. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study
  5. 0.09% CPC + Zinc Lactate Mouthwashapproved, new study

and 4 more — sign in to see them all

26%

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Colgate Palmolive9 readouts · 9 phase 3

Colgate Palmolive, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Colgate SNaP Total 10/10, 1.5 Tauratephase 3 · Nov 0 · NCT07605338

Colgate Palmolive, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. 0.09% CPC + Zinc Lactate Mouthwashapproved, new study · Dec 15 · NCT07880509
  2. Prevident 5000ppm Booster Plus Toothpasteapproved, new study · Dec 20 · NCT07819370

Colgate Palmolive, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. 0.45% SnF HW with NaF (1450 F)phase 3 · Jan 0 · NCT07842991
··

Colgate Palmolive, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Silica Free Meridolphase 3 · Apr 0 · NCT07842978

Colgate Palmolive, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oil-balancing sunscreenapproved, new study · May 0 · NCT07932288
···

Colgate Palmolive, Sep ’27: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwashapproved, new study · Sep 0 · NCT07807397
  2. sodium fluoride 5000 ppmapproved, new study · Sep 0 · NCT07807397
  3. Tin Fluoridesapproved, new study · Sep 0 · NCT07807397
·
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Colgate Palmolive

New programs 8

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionColgate PalmoliveSanofi
Diabetes Mellitus, Type 2both · compare here

Colgate Palmolive in Diabetes Mellitus, Type 2: 3 programs

  1. Tin Fluoridesapproved, new study
  2. Cetylpyridiniumapproved, new study
  3. zinc lactateapproved, new study

Their studies: Colgate Palmolive’s studies of Diabetes Mellitus, Type 2 in search

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Acne Vulgarisboth · compare here

Colgate Palmolive in Acne Vulgaris: 1 program

  1. oil-balancing sunscreenapproved, new study

Their studies: Colgate Palmolive’s studies of Acne Vulgaris in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Colgate Palmolive 0 of 35 · Sanofi 54 of 81 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).